

1103326-0901

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Peter Nordberg
Serial No. : TBA
Filed : December 19, 2005
For : Novel Imidazopyridine Compound II with Therapeutic Effect
Examiner : TBA
Group Art Unit : TBA

Express Mail Label: EV 585 054 195 US I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 in an envelope addressed to: Mail Stop PCT, Assistant Commissioner for Patents, Box 1450, Alexandria, VA 22313-1450, on December 19, 2005. <u>BERNARD MAYS</u> Name of person mailing paper or fee <u>Bernard Mays</u> Signature of person mailing paper or fee
--

Mail Stop PCT
Commissioner for Patents
Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit this communication in compliance with 37 C.F.R. §§1.56, 1.97 and 1.98. Favorable consideration of the documents cited on the attached Form PTO/SB/08A is respectfully requested.

The referenced application is the U.S. national stage application of international application no. PCT/SE2004/001013, filed June 23, 2004 (the "PCT application"). The documents identified on the attached Form PTO/SB/08A include documents cited in the specification and/or the International Search Report ("ISR") which issued in connection with the PCT application. Copies of the published PCT application, i.e., International Publication

Number WO 2004/113339, and the ISR are included with this filing. The ISR is attached to and part of the published PCT application.

Copies of Cited U.S. Patent Documents are Not Provided

As announced in the Official Gazette of August 5, 2003, the requirement under 37 CFR 1.98(a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003 has been waived.

Accordingly, copies of the U.S. patents and/or published patent applications cited on the attached Form PTO/SB/08A are not provided with this Information Disclosure Statement.

Time of Transmittal of Information Disclosure Statement

This Information Disclosure Statement is being filed under 37 C.F.R. §1.97(b)(2) concurrently with a new national stage patent application and, therefore, no separate fee is due. However, if any fee is required, the Assistant Commissioner is authorized to charge such fee to Deposit Account No. 23-1703.

Dated: Dec. 19, 2005

Respectfully submitted,

Andrew Fessak

Andrew Fessak
Reg. No. 48,528
Customer No. 007470
White & Case LLP
Direct Dial: (212) 819-8437

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known		
				Application Number		TBA
				Filing Date		December 19, 2005
				First Named Inventor		Peter Nordberg
				Art Unit		TBA
				Examiner Name		TBA
Sheet	1	of	1	Attorney Docket Number		1103326-0901

U.S. PATENT DOCUMENTS					
Examiner Initials [*]	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages/Figures Appear
		Number-Kind Code ² (if known)			
		US 4,450,164	05-22-1984	Bristol et al.	
		US 4,725,601	02-16-1988	Ueda et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials [*]	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		EP-033,094-B1	08-05-1981	Bristol et al.		
		EP-204,285-B1	12-10-1986	Ueda et al.		
		WO-99/55705-A1	11-04-1999	Amin et al.		
		WO-99/55706-A1	11-04-1999	Amin et al.		
		WO-00/11000-A2	03-02-2000	Amin et al.		
		WO-02/064118-A1	08-22-2002	Anne Juppo		
		WO-03/018582-A1	03-06-2003	Amin et al.		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		KAMINSKI et al., "Antiulcer Agents. 1. Gastric Antisecretory and Cytoprotective Properties of Substituted Imidazo[1,2-a]pyridines"; J. Med. Chem., vol. 28, 876-892, (1985)	
		KAMINSKI et al., "Antiulcer Agents. 2. Gastric Antisecretory, Cytoprotective, and Metabolic Properties of Substituted Imidazo[1,2-a]pyridines and Analogues"; J. Med. Chem., vol. 30, 2031-2046, (1987)	
		KAMINSKI et al., "Antiulcer Agents. 3. Structure-Activity-Toxicity Relationships of Substituted Imidazo[1,2-a]pyridines and a Related Imidazo[1,2-a]pyrazine"; J. Med. Chem., vol. 30, 2047-2051, (1987)	
		KAMINSKI et al., "Antiulcer Agents. 4. Conformational Considerations and the Antiulcer Activity of Substituted Imidazo[1,2-a]pyridines and Related Analogues"; J. Med. Chem., vol. 32, 1686-1700, (1989)	
		KAMINSKI et al., "Antiulcer Agents. 5. Inhibition of Gastric H ⁺ /K ⁺ -ATPase by Substituted Imidazo[1,2-a]pyridines and Related Analogues and Its Implication in Modeling the High Affinity Potassium Ion Binding Site of the Gastric Proton Pump Enzyme"; J. Med. Chem., vol. 34, 533-541, (1991)	
		SACHS et al., "The Pharmacology of the Gastric Acid Pump: The H ⁺ /K ⁺ -ATPase"; Annu. Rev. Pharmacol. Toxicol. 35: 277-305, (1995)	
		BERGLINDH et al., "Effects of Secretagogues on Oxygen Consumption, Aminopyrine Accumulation and Morphology in Isolated Gastric Glands"; Acta Physiol. Scand. 97: 401-414, (1976)	
		LeBEL et al., "A Convenient Method for the ATPase Assay"; Anal. Biochem., 85, 86-89, (1978)	
		POPOVIC et al., "Permanent Cannulation of Aorta and Vena Cava in Rats and Ground Squirrels"; J. Appl. Physiol., 15, 727-728, (1960)	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is in file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.